PsychonautWiki Journal locks drug & interaction tracking behind Paywall

⚠️ Article status notice: This article has been marked as incomplete

This article needs additional work for its sourcing and verifiability to meet the wiki's Content Guidelines and be in line with our Mission Statement for comprehensive coverage of consumer protection issues.

This notice will be removed once sufficient documentation has been added to establish the systemic nature of these issues. Once you believe the article is ready to have its notice removed, please visit the Moderator's noticeboard, or the discord and post to the #appeals channel.

Learn more ▼

This Article Requires Additional Verification

---

This article has been flagged due to verification concerns. While the topic might have merit, the claims presented lack citations that live up to our standards, or rely on sources that are questionable or unverifiable by our standards. Articles must meet the Moderator Guidelines and Mission statement; factual accuracy and systemic relevance are required for inclusion here!

Why This Article Is In Question

---

Articles in this wiki are required to:

• Provide verifiable & credible evidence to substantiate claims.
• Avoid relying on anecdotal, unsourced, or suspicious citations that lack legitimacy.
• Make sure that all claims are backed by reliable documentation or reporting from reputable sources.

Examples of issues that trigger this notice:

• A topic that heavily relies on forum posts, personal blogs, or other unverifiable sources.
• Unsupported claims with no evidence or citations to back them up.
• Citations to disreputable sources, like non-expert blogs or sites known for spreading misinformation.

How You Can Improve This Article

---

To address verification concerns:

• Replace or supplement weak citations with credible, verifiable sources.
• Make sure that claims are backed by reputable reporting or independent documentation.
• Provide additional evidence to demonstrate systemic relevance and factual accuracy. For example:
  • Avoid: Claims based entirely on personal anecdotes or hearsay without supporting documentation.
  • Include: Corporate policies, internal communications, receipts, repair logs, verifiable video evidence, or credible investigative reports.

If you believe this notice has been placed in error, or once the article has been updated to address these concerns, please visit the #appeals channel on our Discord server: Join here.

In September 2025, the app PsychonautWiki Journal was updated to Version 12.0 on both Android and iOS. This update came with a new restriction on drug & interaction tracking that was provided without warning prior to the update.

Background

PsychonaughtWiki Journal is an application developed by Isaak Hanimann released in 2021. PsychonautWiki Journal is a medication & drug tracking app, designed first and foremost for substance users, but is also usable for tracking of typical prescription medication. It allows users to track their medication use as well as potential drug interactions, including potentially severe negative interactions with psychedelic or perception-altering substances and allows substance users to safely plan tolerance breaks to prevent overuse.

Version 12.0 Premium tier lockout

On the 4th of September 2025, Version 12.0 of PsychonautWiki Journal was released on the iOS App Store and Google Play Store. This update added [Stub]

In addition to the other features in this release, users who updated the app were met with a prompt to upgrade to Premium, with the restriction that users would continue to be able to track their three most-used drugs for free.

This change was not warned in advance of the update, and users would find themselves logging in to track a substance only to be entirely unable to because they were not presented with the option to choose what preferred drugs remained trackable, or with a warned grace period.

Isaak's response

Upon opening the prompt, the user is met with a message saying; "PsychonautWiki Journal is free for anyone who can't afford it. In that case send a message to [email protected]". As of yet users have not been met with any negative response.

Consumer response

This section is unfinished.